Find information on thousands of medical conditions and prescription drugs.

Tracleer

Bosentan is an endothelin receptor antagonist important in the treatment of pulmonary artery hypertension.

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
Oxytetracycline
Phentermine
Tacrine
Tacrolimus
Tagamet
Talbutal
Talohexal
Talwin
Tambocor
Tamiflu
Tamoxifen
Tamsulosin
Tao
Tarka
Taurine
Taxol
Taxotere
Tazarotene
Tazobactam
Tazorac
Tegretol
Teicoplanin
Telmisartan
Temazepam
Temocillin
Temodar
Temodar
Temozolomide
Tenex
Teniposide
Tenoretic
Tenormin
Tenuate
Terazosin
Terbinafine
Terbutaline
Terconazole
Terfenadine
Teriparatide
Terlipressin
Tessalon
Testosterone
Tetrabenazine
Tetracaine
Tetracycline
Tetramethrin
Thalidomide
Theo-24
Theobid
Theochron
Theoclear
Theolair
Theophyl
Theophyl
Theostat 80
Theovent
Thiamine
Thiomersal
Thiopental sodium
Thioridazine
Thorazine
Thyroglobulin
Tiagabine
Tianeptine
Tiazac
Ticarcillin
Ticlopidine
Tikosyn
Tiletamine
Timolol
Timoptic
Tinidazole
Tioconazole
Tirapazamine
Tizanidine
TobraDex
Tobramycin
Tofranil
Tolazamide
Tolazoline
Tolbutamide
Tolcapone
Tolnaftate
Tolterodine
Tomoxetine
Topamax
Topicort
Topiramate
Tora
Toradol
Toremifene
Tracleer
Tramadol
Trandate
Tranexamic acid
Tranxene
Tranylcypromine
Trastuzumab
Trazodone
Trenbolone
Trental
Trest
Tretinoin
Triacetin
Triad
Triamcinolone
Triamcinolone hexacetonide
Triamterene
Triazolam
Triclabendazole
Triclosan
Tricor
Trifluoperazine
Trilafon
Trileptal
Trimetazidine
Trimethoprim
Trimipramine
Trimox
Triprolidine
Triptorelin
Tritec
Trizivir
Troglitazone
Tromantadine
Trovafloxacin
Tubocurarine chloride
Tussionex
Tylenol
Tyrosine
U
V
W
X
Y
Z

Read more at Wikipedia.org


[List your site here Free!]


Medication approved to treat rare lung disorder - Updates - Tracleer - Brief Article
From FDA Consumer, 3/1/02

The FDA has approved Tracleer (bosentan) tablets to improve the aerobic abilities of people with a rare but fatal lung disorder called pulmonary arterial hypertension (PAH).

PAH is defined as abnormally high blood pressure in the arteries between the heart and lungs. The condition reduces the ability to exert oneself physically without becoming short of breath. PAH significantly shortens the lire span because it leads to heart failure.

Tracleer blocks the action of endothelin, a substance made in the body that narrows blood vessels and elevates blood pressure. In two clinical trials involving 245 people, treatment with Tracleer significantly increased the six-minute walking distance of those taking the drug, compared to those taking an inactive pill (placebo). In both studies, Tracleer or the placebo was given in addition to any other medications that were prescribed.

The use of Tracleer requires attention to two significant risks: liver toxicity and the drug's potential to damage a fetus. To ensure careful monitoring for these risks, Tracleer will only be available through a direct distribution program from the drug's manufacturer, Actelion Pharmaceuticals US Inc. of South San Francisco, Calif.

Tracleer's warning information states that liver enzyme levels must be measured before initiation of treatment with the drug and monthly thereafter to avoid liver injury. To date, the elevation of liver enzymes caused by Tracleer has been resolved without causing permanent liver damage.

Because of its potential to cause birth defects, Tracleer must not be prescribed to pregnant women. Female patients of childbearing age must take measures to prevent pregnancy, and monthly pregnancy testing will be required. Oral, injected, and implanted contraceptives may not be reliable because Tracleer may alter a woman's metabolism in a way that reduces their effectiveness. So women who take Tracleer must consult with a gynecologist or other doctor knowledgeable about contraceptives.

COPYRIGHT 2002 U.S. Government Printing Office
COPYRIGHT 2004 Gale Group

Return to Tracleer
Home Contact Resources Exchange Links ebay